Literature DB >> 3126257

Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity.

P Ralph1, I Nakoinz, D Rennick.   

Abstract

Pretreatment of murine peritoneal exudate macrophages with 1-5 U/ml rIFN-gamma or rIL-2, or higher concentrations of IFN-alpha or IFN-beta greatly stimulated ADCC to Rl lymphoma targets. The assay was direct counting of viable target cells after 9 and 24 h using an E/T ratio of 5:1. 2d of pretreatment was optimal for enhancing ADCC. rIL-4 was inactive and IL-4-depleted Con A-induced spleen lymphokine retained its ADCC-stimulating activity. Antibody to IFN-gamma blocked the ADCC-promoting effect of the lymphokine, suggesting a major role for this factor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126257      PMCID: PMC2188823          DOI: 10.1084/jem.167.2.712

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

1.  Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes.

Authors:  P Ralph; I Nakoinz
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

2.  Distinct signals for antibody-dependent and nonspecific killing of tumor targets mediated by macrophages.

Authors:  P Ralph; N Williams; I Nakoinz; H Jackson; J D Watson
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

3.  Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1.

Authors:  J Ohara; W E Paul
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

4.  Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.

Authors:  M Malkovský; B Loveland; M North; G L Asherson; L Gao; P Ward; W Fiers
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

5.  B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens.

Authors:  R M Crawford; D S Finbloom; J Ohara; W E Paul; M S Meltzer
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

6.  Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells.

Authors:  D Rennick; G Yang; C Muller-Sieburg; C Smith; N Arai; Y Takabe; L Gemmell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

7.  Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.

Authors:  W J Johnson; Z Steplewski; T J Matthews; T A Hamilton; H Koprowski; D O Adams
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

8.  Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon.

Authors:  R D Schreiber; J L Pace; S W Russell; A Altman; D H Katz
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  Stimulation of macrophage tumoricidal activity by the growth and differentiation factor CSF-1.

Authors:  P Ralph; I Nakoinz
Journal:  Cell Immunol       Date:  1987-04-01       Impact factor: 4.868

10.  Macrophage activation selectively enhances expression of Fc receptors for IgG2a.

Authors:  R A Ezekowitz; M Bampton; S Gordon
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Interleukin-4. A regulatory protein.

Authors:  J H Jansen; W E Fibbe; R Willemze; J C Kluin-Nelemans
Journal:  Blut       Date:  1990-05

2.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.

Authors:  P H Hart; G F Vitti; D R Burgess; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

4.  Differential regulation of tumour necrosis factor-alpha mRNA degradation in macrophages by interleukin-4 and interferon-gamma.

Authors:  K Suk; K L Erickson
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

5.  Regulation of murine macrophage function by IL-4: IL-4 and IFN-gamma differentially regulate macrophage tumoricidal activation.

Authors:  K Suk; S D Somers; K L Erickson
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

6.  Respiratory burst capacity of activated macrophages is resistant to depression by erythrocyte phagocytosis.

Authors:  M G Schwacha; D J Loegering
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

7.  Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.

Authors:  A M Liberati; M Horisberger; M Schippa; F Di Clemente; M Fizzotti; S Filippo; M G Proietti; S Arzano; P Berruto; L Palmisano
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking.

Authors:  A Eisenthal; V Ramakrishna; Y Skornick; M Shinitzky
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

9.  Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules.

Authors:  A Eisenthal; J K McIntosh
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.

Authors:  K Y Tsang; M D Finch; F J Primus; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.